Although our study has confirmed STAT3 as a potential target for SJZD treatment in GC, further experimental validation in vitro or in vivo is still required to fully elucidate the underlying mechanisms of the effects of SJZD on GC. This evidence concerns the gene STAT3 and gastric cancer.